Patent · US Expired

Equine herpesvirus recombinant poxvirus vaccine

US5482713A · kind A · utility

58Cited by
1References
11Claims
0Family size

Assignee

Inventor

Key dates

Filing dateSep 21, 1993
Grant dateJan 9, 1996
Priority date
Expiry dateSep 21, 2013

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2770/20022
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from herpesvirus. In one embodiment, the foreign DNA is expressed in a host by the production of a herpesvirus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two, particularly two or three, herpesvirus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, the barrier of maternal immunity in a newborn offspring can be overcome or avoided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.